Clinical Stage Oncology for Early Cancer Detection 1440

The Company is a clinical-stage oncology company with a platform that combines biospectral impedance and AI/ML for point-of-care cancer detection. The lead product delivers rapid, in-procedure assessment of surgical margins—identifying the presence and location of cancer within minutes. Initial commercialization targets skin cancer, where the lead product can shorten procedures, spare healthy tissue, improve surgeon economics, and enhance outcomes. The Company has also built a compelling breast cancer dataset and plans to deploy the lead product to help dramatically reduce the ~20–25% re-surgery (re-excision) rate in partial mastectomies; the breast program is in line for non-dilutive CPRIT support. The Company has a collaboration with PHC Holdings (formerly Panasonic Healthcare; TSE:6529) to commercialize the lead product. The company anticipates FDA clearance in 2026 and profitability in 2028. Beyond skin and breast, the Company has generated promising data in lung, pancreatic, esophageal, and colon tissue. Follow-on products include a rapid biopsy-assessment device and a needle-based device leveraging the same platform. Use of Proceeds: This round will fund FDA clearance activities and the initial commercial launch of the lead product. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Leased. Competition: The Company is well-positioned: offering a technology type (bioelectric / impedance + AI) that is one of the promising directions in margin detection, with some advantages in potential cost, portability, and multi-tissue applicability. Growth & Expansion: The Company has already taken several concrete steps that are helping it scale / expand. Some of the key ones: strategic partnerships and distribution agreements, approaching product launch timeline as well as development of highly experienced advisors. Financing: TBD if structure and terms are acceptable. Support & Training: As needed – specific terms for transition support can be negotiated. Reason for Selling: Raise capital to secure FDA clearance and launch.